| Withdrawn | Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. NCT04290871 | Xijing Hospital | Phase 2 |
| Unknown | Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 NCT05054075 | Universidade do Porto | Phase 2 |
| Withdrawn | Characteristics of Patients With COVID-19 in Meta State, Colombia NCT04456426 | Hospital Departamental de Villavicencio | — |
| Completed | A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Tes NCT05107258 | Pine Trees, Inc. | — |
| Completed | Quercetin In The Treatment Of SARS-COV 2 NCT04853199 | Hôpital Universitaire Sahloul | EARLY_Phase 1 |
| Completed | EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 NCT04822818 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Follow-up of Covid-19 Long Term Sequelae NCT05097677 | Azienda Ospedaliera Universitaria Integrata Verona | — |
| Completed | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety o NCT04629703 | Rigel Pharmaceuticals | Phase 3 |
| Completed | Sisonke (Together): OPEN LABEL TRIAL COVID-19 NCT04838795 | Wits Health Consortium (Pty) Ltd | Phase 3 |
| Withdrawn | Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit NCT04853927 | Applied Biology, Inc. | Phase 3 |
| Completed | Proxalutamide Treatment for Hospitalized COVID-19 Patients NCT04728802 | Applied Biology, Inc. | Phase 3 |
| Terminated | Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19) NCT04664075 | Imperial College London | — |
| Completed | Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infec NCT04649931 | B. Braun Melsungen AG | — |
| Completed | Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) NCT05074719 | University of Washington | — |
| Completed | Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 NCT04644159 | Institut Pasteur | — |
| Unknown | A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 NCT04540185 | Biomed Industries, Inc. | Phase 3 |
| Withdrawn | Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19 NCT04590274 | International Brain Research Foundation | Phase 1 |
| Unknown | Colloidal Silver, Treatment of COVID-19 NCT04978025 | Hôpital Universitaire Sahloul | N/A |
| Completed | Anti-Androgen Treatment for COVID-19 NCT04446429 | Applied Biology, Inc. | N/A |
| Completed | Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan NCT04701710 | Maria de los Angeles Peral de Bruno | Phase 1 / Phase 2 |
| Completed | Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) NCT04546581 | University of Minnesota | Phase 3 |
| Unknown | Home-based Exercise in COVID-19 Survivors NCT04615052 | University of Sao Paulo | N/A |
| Completed | A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusio NCT04720794 | Lucira Health Inc | N/A |
| Unknown | Adolescents With COVID-19/MIS-C at HCFMUSP NCT04659486 | University of Sao Paulo | N/A |
| Completed | Ivermectin Reproposing for Mild Stage COVID-19 Outpatients NCT04784481 | Ministry of Public Health, Argentina | Phase 1 / Phase 2 |
| Completed | Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study) NCT04584658 | Cambridge University Hospitals NHS Foundation Trust | — |
| Completed | Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation NCT04558476 | University of Liege | Phase 2 |
| Completed | Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19 NCT04476979 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Glycine Supplement for Severe COVID-19 NCT04443673 | Instituto Nacional de Enfermedades Respiratorias | N/A |
| Terminated | Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 NCT04327505 | Karolinska Institutet | Phase 2 / Phase 3 |
| Completed | Renal Biomarkers in AKI and COVID-19 NCT04517630 | Instituto Nacional de Enfermedades Respiratorias | — |
| Terminated | Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms NCT04382391 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | N/A |
| Unknown | Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) NCT04497454 | University of Sao Paulo General Hospital | N/A |
| Completed | Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome NCT04366908 | Maimónides Biomedical Research Institute of Córdoba | Phase 2 |
| Unknown | Low Dose Radiotherapy in COVID-19 Pneumonia NCT04390412 | Shahid Beheshti University of Medical Sciences | Phase 1 / Phase 2 |
| Unknown | High Flow Nasal Cannula HFNC In Covid-19 Patients NCT04560257 | Lahore General Hospital | N/A |
| Unknown | Methylprednisolone in COVID-19 Patients (Methyl19LGH) NCT04559113 | Lahore General Hospital | N/A |
| Withdrawn | Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) NCT04361461 | Apsen Farmaceutica S.A. | Phase 3 |
| Completed | Quantification of Radiological Pulmonary Involvement in Acute Respiratory Failure NCT04374734 | University Hospital, Strasbourg, France | — |
| Completed | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) NCT04328961 | University of Washington | Phase 2 / Phase 3 |
| Completed | Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area NCT04480580 | University of Cagliari | — |
| Completed | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 NCT04306393 | Massachusetts General Hospital | Phase 2 |
| Completed | Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France NCT04325646 | Institut Pasteur | — |
| Available | Expanded Access to Zofin for Patients With COVID-19 NCT04657406 | ZEO ScientifiX, Inc. | — |